-
Uniqure NV NASDAQ:QURE uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases.
Location: | Website: www.uniqure.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
825.3M
Cash
435.2M
Avg Qtr Burn
-44.86M
Short % of Float
8.36%
Insider Ownership
8.48%
Institutional Own.
80.61%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
HEMGENIX® (etranacogene dezaparvovec-drlb) (AMT-061) Details Hemophilia, Rare diseases, Rare genetic disease | Approved Quarterly sales | |
AMT-162 Details Amyotrophic lateral sclerosis | Phase 1/2 Data readout | |
AMT-260 Details Epilepsy, Mesial temporal lobe epilepsy | Phase 1/2 Data readout | |
AMT-191 Details Fabry disease, Genetic disorder | Phase 1/2 Data readout | |
AMT-130 Details Huntington's disease, Genetic disorder | Phase 1/2 Data readout |